<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>News and Trends on Pharma Industry Production &amp; Manufacturing</title>
	<atom:link href="https://www.worldpharmatoday.com/production-manufacturing/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.worldpharmatoday.com</link>
	<description>Magazine for the C-level Pharma Executives</description>
	<lastBuildDate>Fri, 26 Jun 2026 06:23:54 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://www.worldpharmatoday.com/wp-content/uploads/2025/12/cropped-World-Pharma-Today-fevicon-32x32.jpg</url>
	<title>News and Trends on Pharma Industry Production &amp; Manufacturing</title>
	<link>https://www.worldpharmatoday.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Cell and Gene Therapy Delivery Challenges Evolving Now</title>
		<link>https://www.worldpharmatoday.com/biopharma/cell-and-gene-therapy-delivery-challenges-evolving-now/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 26 Jun 2026 06:23:54 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/cell-and-gene-therapy-delivery-challenges-evolving-now/</guid>

					<description><![CDATA[<p>We are currently standing at the threshold of a medical revolution, transitioning from a model of managing chronic conditions to one of potentially curing genetic diseases at their foundational level. The promise of advanced therapeutics such as CRISPR-based gene editing and CAR-T cell therapies is immense, offering hope for conditions that were once considered incurable. [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/biopharma/cell-and-gene-therapy-delivery-challenges-evolving-now/">Cell and Gene Therapy Delivery Challenges Evolving Now</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Continuous Manufacturing Reshaping Drug Formulation</title>
		<link>https://www.worldpharmatoday.com/techno-trends/continuous-manufacturing-reshaping-drug-formulation/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 26 Jun 2026 06:23:43 +0000</pubDate>
				<category><![CDATA[Drug Research]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<category><![CDATA[Techno Trends]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/continuous-manufacturing-reshaping-drug-formulation/</guid>

					<description><![CDATA[<p>Continuous manufacturing drug formulation represents the most significant leap in pharmaceutical engineering in over a century, fundamentally altering how medications are conceived, developed, and delivered to the global market. For decades, the industry operated under the batch manufacturing paradigm, a fragmented process where materials move through discrete steps mixing, granulating, drying, and compressing with long [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/techno-trends/continuous-manufacturing-reshaping-drug-formulation/">Continuous Manufacturing Reshaping Drug Formulation</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Shilpa Biologicals Launches PartnerPower Platform for CDMOs</title>
		<link>https://www.worldpharmatoday.com/press-releases/shilpa-biologicals-launches-partnerpower-platform-for-cdmos/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Wed, 24 Jun 2026 08:54:08 +0000</pubDate>
				<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/shilpa-biologicals-launches-partnerpower-platform-for-cdmos/</guid>

					<description><![CDATA[<p>Shilpa Biologicals Pvt. Ltd. (SBPL) has introduced PartnerPower Platform, a proprietary digital transparency solution designed to provide global sponsors with continuous, real-time visibility across biologics development and manufacturing activities. Announced on 22 June 2026 from Dharwad, India, the platform is intended to give biopharmaceutical innovators uninterrupted access to project information, enabling them to monitor progress [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/press-releases/shilpa-biologicals-launches-partnerpower-platform-for-cdmos/">Shilpa Biologicals Launches PartnerPower Platform for CDMOs</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Alzheimer’s Drug Packaging Expansion Receives UK Funding</title>
		<link>https://www.worldpharmatoday.com/news/alzheimers-drug-packaging-expansion-receives-uk-funding/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Wed, 17 Jun 2026 12:37:04 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Packaging & Labelling]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/alzheimers-drug-packaging-expansion-receives-uk-funding/</guid>

					<description><![CDATA[<p>Eisai is moving ahead with a major upgrade of its manufacturing facility in Hatfield, Hertfordshire, backed by support from the United Kingdom’s Life Sciences Innovative Manufacturing Fund (LSIMF). The Japanese drugmaker is investing approximately 48 million pounds sterling ($64.5 million) to expand the site and introduce new cold-chain supply and packaging capabilities for medicines that [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/alzheimers-drug-packaging-expansion-receives-uk-funding/">Alzheimer’s Drug Packaging Expansion Receives UK Funding</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Recipharm Investment Expands US Sterile Manufacturing</title>
		<link>https://www.worldpharmatoday.com/news/recipharm-investment-expands-us-sterile-manufacturing/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Wed, 17 Jun 2026 12:29:17 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/recipharm-investment-expands-us-sterile-manufacturing/</guid>

					<description><![CDATA[<p>Recipharm has unveiled a multi-million-dollar investment in its US operations aimed at increasing sterile fill and finish manufacturing capacity for biologics and advanced therapies. The expansion comes after the company secured a clinical biologics fill and finish agreement with a major global pharmaceutical company and is intended to broaden capabilities spanning development, scale-up, clinical production [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/recipharm-investment-expands-us-sterile-manufacturing/">Recipharm Investment Expands US Sterile Manufacturing</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>MGS Advances Healthcare Product Development with Hybrid Tooling</title>
		<link>https://www.worldpharmatoday.com/press-releases/mgs-advances-healthcare-product-development-with-hybrid-tooling/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Sat, 13 Jun 2026 05:41:10 +0000</pubDate>
				<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/mgs-advances-healthcare-product-development-with-hybrid-tooling/</guid>

					<description><![CDATA[<p>MGS, a healthcare-focused contract development and manufacturing organization, has expanded its Hybrid Tooling capability worldwide after successfully deploying the approach alongside its A.i.r. Platform™. The company said the broader rollout is intended to help healthcare manufacturers accelerate product development, lower development risks and progress from concept to commercialization with greater confidence. The expanded offering is [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/press-releases/mgs-advances-healthcare-product-development-with-hybrid-tooling/">MGS Advances Healthcare Product Development with Hybrid Tooling</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Daewoong and Chime Biologics Partner for Biosimilar Push</title>
		<link>https://www.worldpharmatoday.com/news/daewoong-and-chime-biologics-partner-for-biosimilar-push/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Wed, 10 Jun 2026 12:09:36 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<category><![CDATA[Biopharmaceutical Development]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/daewoong-and-chime-biologics-partner-for-biosimilar-push/</guid>

					<description><![CDATA[<p>Chime Biologics and Daewoong Pharmaceutical have entered into a strategic collaboration to develop and manufacture a dupilumab biosimilar candidate referencing Dupixent for global markets. The partnership, announced by VMS Group, combines the development and manufacturing capabilities of Chime Biologics with Daewoong Pharmaceutical’s plans to expand its presence in the international biosimilars sector. Through this initiative, [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/daewoong-and-chime-biologics-partner-for-biosimilar-push/">Daewoong and Chime Biologics Partner for Biosimilar Push</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Aragen Backs Renaissance Rare Disease Therapy Launch</title>
		<link>https://www.worldpharmatoday.com/news/aragen-backs-renaissance-rare-disease-therapy-launch/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Wed, 03 Jun 2026 13:23:21 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/aragen-backs-renaissance-rare-disease-therapy-launch/</guid>

					<description><![CDATA[<p>Contract research, development, and manufacturing organization (CRDMO) Aragen has announced the successful production of the first commercial-scale GMP batches of Daretabart (hu1418K322A), the lead therapeutic candidate of UK-based Renaissance Pharma Limited. The milestone marks a key step forward in the development of a treatment targeting high-risk neuroblastoma (HRNB), an aggressive and rare form of pediatric [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/aragen-backs-renaissance-rare-disease-therapy-launch/">Aragen Backs Renaissance Rare Disease Therapy Launch</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Aragen Achieves Daretabart Commercial-scale GMP Production</title>
		<link>https://www.worldpharmatoday.com/press-releases/aragen-achieves-daretabart-commercial-scale-gmp-production/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Wed, 03 Jun 2026 11:50:39 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/aragen-achieves-daretabart-commercial-scale-gmp-production/</guid>

					<description><![CDATA[<p>Aragen, a global leader in Contract Research, Development, and Manufacturing Organization (CRDMO) services, has announced the successful technology transfer and commercial-scale GMP manufacturing of the first batches of Daretabart, Renaissance Pharma’s lead therapeutic candidate for high-risk neuroblastoma. The milestone was achieved within just nine months, highlighting the efficiency of the collaboration between the two organizations. [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/press-releases/aragen-achieves-daretabart-commercial-scale-gmp-production/">Aragen Achieves Daretabart Commercial-scale GMP Production</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>CordenPharma Seals AmbioPharm Deal to Expand Global Network</title>
		<link>https://www.worldpharmatoday.com/press-releases/cordenpharma-seals-ambiopharm-deal-to-expand-global-network/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Sat, 30 May 2026 08:25:37 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<category><![CDATA[Acquisition]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/cordenpharma-seals-ambiopharm-deal-to-expand-global-network/</guid>

					<description><![CDATA[<p>CordenPharma, a global contract development and manufacturing organization specializing in complex drug modalities, has officially entered into an agreement to acquire AmbioPharm. The AmbioPharm Deal strengthens the company’s manufacturing presence in the United States while adding newly integrated production capabilities in Shanghai, China. The move allows CordenPharma to comprehensively support the growing global demand for [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/press-releases/cordenpharma-seals-ambiopharm-deal-to-expand-global-network/">CordenPharma Seals AmbioPharm Deal to Expand Global Network</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
	</channel>
</rss>
